{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-106399","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2023-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.844493+00:00","generated_at":"2026-06-10T05:23:48.186192+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ocular Therapeutix initiates first pivotal trial of OTX-TKI for wet AMD","bullets":["Activated first US clinical trial site; expects to enroll first subject by year-end 2023.","Superiority trial of ~300 evaluable treatment-naïve wet AMD subjects randomized to aflibercept or OTX-TKI implant.","Filed Special Protocol Assessment request with FDA for trial design; enrollment will wait for SPA feedback.","OTX-TKI is an axitinib intravitreal implant, a potential long-acting therapy for wet AMD."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-106399","json":"https://secwatch.observer/filing/0001104659-23-106399.json","markdown":"https://secwatch.observer/filing/0001104659-23-106399.md","text":"https://secwatch.observer/filing/0001104659-23-106399.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465923106399/0001104659-23-106399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465923106399/tm2327569d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T05:23:48.186192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}